Although trastuzumab does not bind to human epidermal growth factor receptor 3(HER3),it dephosphorylates HER3 through a previously unknownmechanism.In addition,HER3 is reactivated during prolonged trastuzumab treatmen...Although trastuzumab does not bind to human epidermal growth factor receptor 3(HER3),it dephosphorylates HER3 through a previously unknownmechanism.In addition,HER3 is reactivated during prolonged trastuzumab treatment and upon resistance[1].Previous study showed that tyrosine-protein phosphatase non-receptor type 9(PTPN9)inhibits STAT3/STAT5 signalling by dephosphorylation of epidermal growth factor receptor(EGFR)and human epidermal growth factor receptor 2(HER2)in breast cancer[2],but how this would affect HER3 was not analyzed especially in relation to trastuzumab treatment.We investigated the role of PTPN9 in HER3 signaling in relation to trastuzumab treatment and resistance in HER2 positive breast cancer.The materials and methods applied in this research were described in the supplementary materials.展开更多
基金supported by Breakthrough Breast cancer(Grant number:CSFKong)through Holbeck Charitable TrustProf A Shaaban is supported by Birmingham CRUK Centre grant.
文摘Although trastuzumab does not bind to human epidermal growth factor receptor 3(HER3),it dephosphorylates HER3 through a previously unknownmechanism.In addition,HER3 is reactivated during prolonged trastuzumab treatment and upon resistance[1].Previous study showed that tyrosine-protein phosphatase non-receptor type 9(PTPN9)inhibits STAT3/STAT5 signalling by dephosphorylation of epidermal growth factor receptor(EGFR)and human epidermal growth factor receptor 2(HER2)in breast cancer[2],but how this would affect HER3 was not analyzed especially in relation to trastuzumab treatment.We investigated the role of PTPN9 in HER3 signaling in relation to trastuzumab treatment and resistance in HER2 positive breast cancer.The materials and methods applied in this research were described in the supplementary materials.
